BENEFITS OF PROPHYLACTIC USE OF PERSONALIZED INSOLES FOR PATIENTS TREATED WITH REGORAFENIB

被引：0
|
作者：
Tsuji, Yasushi [1 ]
Kitayama, Hiromitsu [1 ]
Sugiyama, Junko [1 ]
Sugimoto, Hisashi [2 ]
Takasaki, Syuichi [3 ]
Mitsuno, Kaoru [4 ]
Hirayama, Masaaki [5 ]
机构：
[1] Tonan Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan
[2] Tonan Hosp, Dept Rehabil Serv, Sapporo, Hokkaido, Japan
[3] Tonan Hosp, Dept Pharmacol, Sapporo, Hokkaido, Japan
[4] Tonan Hosp, Nursing Off, Sapporo, Hokkaido, Japan
[5] Tonan Hosp, Dept Gastroenterol, Sapporo, Hokkaido, Japan
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu396.1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SS-2
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib
    Santangelo, Alessandra
    Rossato, Marzia
    Lombardi, Giuseppe
    Benfatto, Salvatore
    Lavezzari, Denise
    De Salvo, Gian Luca
    Indraccolo, Stefano
    Dechecchi, Maria Cristina
    Prandini, Paola
    Gambari, Roberto
    Scapoli, Chiara
    Di Gennaro, Gianfranco
    Caccese, Mario
    Eoli, Marica
    Ruda, Roberta
    Brandes, Alba Ariela
    Ibrahim, Toni
    Rizzato, Simona
    Lolli, Ivan
    Lippi, Giuseppe
    Delledonne, Massimo
    Zagonel, Vittorina
    Cabrini, Giulio
    NEURO-ONCOLOGY, 2021, 23 (02) : 264 - 276
  • [22] Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib
    Vincenzo Ricci
    Cristina Granetto
    Antonella Falletta
    Matteo Paccagnella
    Andrea Abbona
    Elena Fea
    Teresa Fabozzi
    Cristiana Lo Nigro
    Marco Carlo Merlano
    World Journal of Gastrointestinal Oncology, 2020, (03) : 301 - 310
  • [23] Prognostic implication of serum AFP in patients with hepatocellular carcinoma treated with regorafenib
    Lim, Dong-Hoon
    Casadei-Gardini, Andrea
    Lee, Myung Ah
    Lonardi, Sara
    Kim, Jin Won
    Masi, Gianluca
    Chon, Hong Jae
    Rimini, Margherita
    Kim, Ilhwan
    Cheon, Jaekyung
    Hwang, Jun-Eul
    Kang, Jung Hun
    Lim, Ho Yeong
    Yoo, Changhoon
    FUTURE ONCOLOGY, 2022, 18 (27) : 3021 - 3030
  • [24] Impact of sarcopenia in patients with advanced or recurrent colorectal cancer treated with regorafenib
    Murachi, Yasushi
    Sakai, Daisuke
    Koseki, Jun
    Inagaki, Chiaki
    Nishida, Naohiro
    Yamaguchi, Toshifumi
    Satoh, Taroh
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (02) : 409 - 416
  • [25] Impact of sarcopenia in patients with advanced or recurrent colorectal cancer treated with regorafenib
    Yasushi Murachi
    Daisuke Sakai
    Jun Koseki
    Chiaki Inagaki
    Naohiro Nishida
    Toshifumi Yamaguchi
    Taroh Satoh
    International Journal of Clinical Oncology, 2021, 26 : 409 - 416
  • [26] Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib
    Ricci, Vincenzo
    Granetto, Cristina
    Falletta, Antonella
    Paccagnella, Matteo
    Abbona, Andrea
    Fea, Elena
    Fabozzi, Teresa
    Lo Nigro, Cristiana
    Merlano, Marco Carlo
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2020, 12 (03) : 301 - 310
  • [27] The prognostic role of polypharmacy in metastatic colorectal cancer patients treated with regorafenib
    Yekeduz, Emre
    Aktas, Elif Gizem
    Koksoy, Elif Berna
    Dogan, Neslihan
    Urun, Yuksel
    Utkan, Gungor
    FUTURE ONCOLOGY, 2022, 18 (09) : 1067 - 1076
  • [28] USE OF PROPHYLACTIC ANTIBIOTICS IN SURGICAL PATIENTS
    SANDUSKY, WR
    SURGICAL CLINICS OF NORTH AMERICA, 1980, 60 (01) : 83 - 92
  • [29] PROPHYLACTIC USE OF FLUOROQUINOLONES IN NEUTROPENIC PATIENTS
    BRODSKY, AL
    MINISSALE, CJ
    MELERO, MJ
    AVALOS, JCS
    MEDICINA-BUENOS AIRES, 1993, 53 (05) : 401 - 407
  • [30] Prophylactic use of factor VIII: Are the clinical benefits worth the additional cost?
    Bohn, RL
    Avorn, J
    Glynn, RJ
    Choodnovskiy, I
    Haschemeyer, R
    Aledort, LM
    BLOOD, 1995, 86 (10) : 2431 - 2431
12345